**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      D.C. 20549**





**Form
      10-Q**





(Mark
      One)





x
            QUARTERLY
                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                ACT OF
                1934





**For
      the quarterly period ended July 31, 2007**





o
            TRANSITION
                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                ACT OF
                1934





For
      the
      transition period from _______________ to _______________.








**Commission
      file number:** **O-24512**





**RENHUANG
      PHARMACEUTICALS, INC.**


(Exact
      name of registrant as specified in its charter)





**Nevada**
              (State
                or other jurisdiction of
              incorporation
                or organization)
            **88-1273503**
              (I.R.S.
                Employer
              Identification
                No.)**No.
                281, Taiping Road, Taiping District,**
              **Harbin,
                Heilongjiang Province, 150050, P. R. China**
              (Address
                of principal executive offices)





**Registrant’s
      telephone number, including area code 86-451-5762-0378**





Indicate
      by check mark whether the registrant (1) has filed all reports required to
      be
      filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
      the
      preceding 12 months (or for such shorter period that the registrant was required
      to file such reports), and (2) has been subject to such filing requirements
      for
      the past 90 days. Yes x    No
o





Indicate
      by check mark whether the registrant is a large accelerated filer, an
      accelerated filer, or a non-accelerated filer. See definition of “accelerated
      filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check
      one):





Large
      accelerated filer o  Accelerated
      filer o Non-accelerated filer
x





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act). Yes o  No
x





**Applicable
      only to issuers involved in bankruptcy proceedings during the preceding five
      years:**





Indicate
      by check mark whether the registrant has filed all documents and reports
      required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange
      Act
      of 1934 subsequent to the distribution of securities under a plan confirmed
      by a
      court. Yes o No
o











**Applicable
      only to corporate issuers:**





Indicate
      the number of shares outstanding of each of the issuer’s classes of common
      stock, as of the latest practicable date. As of August 30, 2007, there were
      35,096,681 shares of common stock, par value $0.001, issued and
      outstanding .











**Renhuang
      Pharmaceuticals, Inc.**





**TABLE
      OF CONTENTS**


**PART
                I**ITEM
                  1
              FINANCIAL
                  STATEMENTS
              1ITEM
                  2
              MANAGEMENT’S
                  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
                  OPERATIONS.
              24ITEM
                  3
              QUANTITATIVE
                  AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
              31ITEM
                  4
              CONTROLS
                  AND PROCEDURES
              31**PART
                II**ITEM
                  1
              LEGAL
                  PROCEEDINGS
              32ITEM
                  1A
              RISK
                  FACTORS
              32ITEM
                  2
              UNREGISTERED
                  SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
              32ITEM
                  3
              DEFAULTS
                  UPON SENIOR SECURITIES
              32ITEM
                  4
              SUBMISSION
                  OF MATTERS TO A VOTE OF SECURITY HOLDERS
              32ITEM
                  5
              OTHER
                  INFORMATION
              32ITEM
                  6
              EXHIBITS
              34








**PART
      I** **- FINANCIAL INFORMATION**





This
      Quarterly Report includes forward-looking statements within the meaning of
      the
      Securities Exchange Act of 1934 (the “Exchange Act”). These statements are based
      on management’s beliefs and assumptions, and on information currently available
      to management. Forward-looking statements include the information concerning
      possible or assumed future results of operations of the Company set forth under
      the heading “Management’s Discussion and Analysis of Financial Condition or Plan
      of Operation.” Forward-looking statements also include statements in which words
      such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“consider” or similar expressions are used.





Forward-looking
      statements are not guarantees of future performance. They involve risks,
      uncertainties and assumptions. The Company’s future results and shareholder
      values may differ materially from those expressed in these forward-looking
      statements. Readers are cautioned not to put undue reliance on any
      forward-looking statements.





**ITEM
      1**  **Financial
      Statements**




1




**RENHUANG
      PHARMACEUTICALS, INC. AND SUBSIDIARIES**




**CONSOLIDATED
      BALANCE SHEETS**


**AS
      OF JULY 31, 2007**




**(Amounts
      in United States Dollars)**




**ASSETS**





**July
                31,**
              **2007**
            
            **October
                31, 2006****(Unaudited)**
            
            **(Audited)****CURRENT
                ASSETS**Cash
                and cash equivalents
            
            $
            53,660
            
            
            1,021,267Trade
                receivables, net (Note 5)
            
            
            7,549,588
            
            
            7,566,096Inventories
                (Note 6)
            
            
            1,507,043
            
            
            622,144Prepaid
                expenses and deposits
            
            
            218,598
            
            
            102,473Other
                receivables
            
            
            67,783
            
            
            1,143,834Short
                term loan (Note 10)
            
            
            9,495,674Deferred
                expenses (Note 9)
            
            
            120,358
            
            
            115,823**TOTAL
                CURRENT ASSETS**
            
            
            19,012,704
            
            
            10,571,637PROPERTY,
                PLANT AND EQUIPMENT (Note 7)
            
            
            2,828,698
            
            
            2,610,285CONSTRUCTION
                IN PROGRESS (Note 8)
            
            
            474,784
            
            
            106,610**TOTAL
                ASSETS**
            
            $
            22,316,186
            
            
            13,288,532







The
      accompanying notes are in integral part of the financial statements




2


**RENHUANG
      PHARMACEUTICALS, INC. AND SUBSIDIARIES**




**CONSOLIDATED
      BALANCE SHEETS**


**AS
      OF JULY 31, 2007**




**(Amounts
      in United States Dollars)**




**LIABILITIES
      AND STOCKHOLDERS' EQUITY**







**July
                31,**
              **2007**
            
            **October
                31,2006****(Unaudited)**
            
            **(Audited)****CURRENT
                LIABILITIES**Accounts
                payables and accruals (Note 11)-
                due to related parties
            
            $
            -
            
            $
            419,910-
                due to third parties
            
            
            583,658
            
            
            366,805Total
                accounts payables and accruals
            
            
            583,658
            
            
            786,715Other
                payables (Note 12)
            
            
            1,675,229
            
            
            1,877,042**TOTAL
                CURRENT LIABILITIES**
            
            
            2,258,887
            
            
            2,663,757**TOTAL
                LIABILITIES**
            
            
            2,258,887
            
            
            2,663,757**STOCKHOLDERS'
                EQUITY**Common
                Stock - Authorized common shares 100,000,000, outstanding number
                of shares
                35,096,681 at par value of 0.001, authorized preferred shares 2,500,000
                (Note 13)
            
            
            35,097
            
            
            35,000Additional
                paid in capital
            
            
            6,627,099
            
            
            6,310,822Reserves
            
            
            2,051,689
            
            
            847,133Retained
                earnings
            
            
            10,632,398
            
            
            3,378,081Accumulated
                other comprehensive income
            
            
            711,016
            
            
            53,739**TOTAL
                STOCKHOLDERS' EQUITY**
            
            
            20,057,299
            
            
            10,624,775**TOTAL
                LIABILITIES AND****STOCKHOLDERS’
                EQUITY**
            
            $
            22,316,186
            
            
            13,288,532





The
        accompanying notes are in integral part of the financial statements
  3





**RENHUANG
      PHARMACEUTICALS, INC. AND SUBSIDIARIES**


**CONSOLIDATED
      STATEMENT OF INCOME**


**FOR
      THE THREE MONTHS AND NIGH MONTHS ENDED JULY 31, 2007**


**(Amounts
      in United States Dollars, Except for Number of Common
      Shares)**





**Three
                Months**
              **Ended**
              **July
                31,**
              **2006
                (Note 21)**
            
            **Three
                Months**
              **Ended**
              **July
                31,**
              **2007**
            
            **Nine
                Months**
              **Ended**
              **July
                31,**
              **2007****(Unaudited)**
            
            **(Unaudited)**
            
            **(Unaudited)**SALES
            
            $
            5,413,875
            
            $
            5,071,331
            
            $
            20,890,656COST
                OF SALES
            
            
            (2,359,503
            )
            
            (2,491,963
            )
            
            (10,184,980
            )GROSS
                PROFIT
            
            
            3,054,372
            
            
            2,579,368
            
            
            10,705,676SELLING
                AND DISTRIBUTION EXPENSES
            
            
            (87,997
            )
            
            (12,178
            )
            
            (134,624
            )ADVERTISING
                EXPENSE
            
            
            
            
            
            (7,588
            )
            
            (180,269
            )GENERAL
                AND ADMINISTRATIVE EXPENSES
            
            
            (287,696
            )
            
            (655,929
            )
            
            (1,292,433
            )(PROVISION
                FOR DOUBTFUL ACCOUNTS)/RECOVERY
            
            
            (18,793
            )
            
            178,040
            
            
            (443,082
            )DEPRECIATION
                AND AMORTIZATION
            
            
            (42,851
            )
            
            (75,205
            )
            
            (213,680
            )INCOME
                FROM OPERATIONS
            
            
            2,617,035
            
            
            2,006,508
            
            
            8,441,588OTHER
                INCOME
            
            
            4,980
            
            
            7,219
            
            
            17,285INCOME
                BEFORE INCOME TAXES
            
            
            2,622,015
            
            
            2,013,727
            
            
            8,458,873INCOME
                TAXES (Note 14)
            
            
            --
            
            
            --
            
            
            --NET
                INCOME
            
            
            2,622,015
            
            $
            2,013,727
            
            $
            8,458,873BASIC
                EARNINGS PER SHARE
            
            
            0.0749
            
            
            0.057
            
            
            0.242DILUTED
                EARNING PER SHARE
            
            
            0.0749
            
            
            0.057
            
            
            0.242AVERAGE
                NUMBER OF COMMON SHARES OUTSTANDING BASIC
            
            
            34,999,601
            
            
            35,058,920
            
            
            35,019,976DILUTED
            
            
            34,999,601
            
            
            35,058,930
            
            
            35,019,982




The
        accompanying notes are in integral part of the financial statements
  4




**RENHUANG
      PHARMACEUTICALS, INC. AND SUBSIDIARIES**


**CONSOLIDATED
      STATEMENT OF CHANGES IN**


**STOCKHOLDERS’
      EQUITY**


**FOR
      THE SIX MONTHS ENDED JULY 31, 2007**


**(Amounts
      in United States Dollars)**







AccumulatedAdditional
            
            
            
            
            
            OtherCommon
            
            Paid-in
            
            
            
            Retained
            
            comprehensive
            
            TotalStock
            
            capital
            
            Reserves
            
            Earnings
            
            income
            
            EquityBalance
                at October 31, 2006 (Audited)
            
            $
            35,000
            
            $
            6,310,822
            
            $
            847,133
            
            $
            3,378,081
            
            $
            53,739
            
            $
            10,624,775Issuance
                of common stock
            
            
            97
            
            
            284,578
            
            
            
            
            
            
            
            
            
            
            
            284,675Net
                income for 3 quarters 2007
            
            
            --
            
            
            --
            
            
            --
            
            
            8,458,873
            
            
            --
            
            
            8,458,873Transfer
                to reserves
            
            
            
            
            
            
            
            
            1,204,556
            
            
            (1,204,556
            )
            
            
            
            
            --Warrants
                issued to director
            
            
            
            
            
            31,699
            
            
            
            
            
            
            
            
            
            
            
            31,699Other
                comprehensive income-
                foreign currency translation
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            657,277
            
            
            657,277Balance
                at July 31, 2007 (Unaudited)
            
            $
            35,097
            
            $
            6,627,099
            
            $
            2,051,689
            
            $
            10,632,398
            
            $
            711,016
            
            $
            20,057,299




The
        accompanying notes are in integral part of the financial statements
  5




**RENHUANG
      PHARMACEUTICALS, INC. AND SUBSIDIARIES**





**CONSOLIDATED
      STATEMENT OF CASH FLOWS**


**FOR
      THE NIGH MONTHS ENDED JULY 31, 2007**


**(Amounts
      in United States Dollars)**





**Nine
                Months Ended July 31, 2007**
            
            **Three
                Months Ended July 31, 2006 (Note 21)****(Unaudited)**
            
            **(Unaudited)****CASH
                FLOWS FROM OPERATING ACTIVITIES:**Net

                income
            
            $
            8,458,873
            
            
            2,622,015Adjustments
                to reconcile net income to net cash fromoperating
                activities :Depreciation
                and amortization
            
            
            213,680
            
            
            43,149Fair
                Value of Warrants Issued
            
            
            31,699Fair
                Value of Shares Issued
            
            
            284,675Changes
                in operating assets and liabilities:Trade
                receivables, net
            
            
            16,508
            
            
            (3,774,835
            )Inventories
            
            
            (884,899
            )
            
            (1,433,249
            )Other
                receivables, net
            
            
            982,113
            
            
            (39,011
            )Deferred
                expenses
            
            
            (4,535
            )Prepaid
                expenses and deposits
            
            
            (160,539
            )Accounts
                payable and accruals-
                Related Parties
            
            
            (419,910
            )
            
            414,959-
                Third Parties
            
            
            45,709
            
            
            415,191Other
                Payable
            
            
            (201,813
            )
            
            365,718**NET
                CASH PROVIDED BY OPERATING ACTIVITIES**
            
            
            8,361,831
            
            
            (1,386,063
            )**CASH
                FLOWS USED IN INVESTING ACTIVITIES:**Short
                - term loan
            
            
            (9,495,674
            )Acquisition
                of property, plant and equipment
            
            
            (114,058
            )
            
            24,074Construction
                in Progress
            
            
            (386,278
            )**NET
                CASH USED IN INVESTING ACTIVITIES**
            
            $
            (9,996,010
            )
            
            24,074




The
        accompanying notes are in integral part of the financial statements
  6




**RENHUANG
      PHARMACEUTICALS, INC. AND SUBSIDIARIES**





**CONSOLIDATED
      STATEMENT OF CASH FLOWS**


**FOR
      THE NIGH MONTHS ENDED JULY, 2007**


**(Amounts
      in United States Dollars)**





**Nine
                Months Ended July 31, 2007**
            
            **Three
                Months Ended July 31, 2006 (Note 21)****(Unaudited)**
            
            **(Unaudited)****NET
                CHANGE IN CASH AND CASH EQUIVALENTS**
            
            
            (1,634,179
            )
            
            (1,410,137
            )EFFECT
                OF EXCHANGE RATE CHANGES ON CASH AND CASHEQUIVALENTS
            
            
            666,572Cash
                and cash equivalents, beginning of period
            
            
            1,021,267
            
            
            3,637,185Cash
                and cash equivalents, end of period
            
            $
            53,660
            
            
            2,227,048**SUPPLEMENTARY
                DISCLOSURE OF NON-CASH INVESTING AND FINANCING
                ACTIVITIES**Issuance
                of common shares on a non-cash basis
            
            
            97Increase
                in additional paid in capital by issuance of common shares on a non-cash
                basis
            
            
            284,578Financing
                services fee related to issuance of common shares on a non-cash
                basis
            
            
            (284,675
            )Warrants
                of 25,000 granted to a director for services on a non-cash
                basis
            
            
            31,699Services
                compensation paid to a director by granting warrants on a non-cash
                basis
            
            
            (31,699
            )Increase
                in construction in progress by assuming a loan on a non-cash
                basis
            
            
            (174,087
            )Increase
                in accounts payable by assuming a loan on a non-cash basis
            
            
            174,087Transfer
                of construction in progress to property, plant, and equipment on
                a
                non-cash basis
            
            
            219,467Property,
                plant, and equipment transferred from construction in progress on
                non-cash
                basis
            
            
            (219,467
            )





The
        accompanying notes are in integral part of the financial statements
  7


**RENHUANG
      PHARMACEUTICALS, INC. AND SUBSIDIARIES**




**NOTES
      TO CONSOLIDATED FINANCIAL STATEMENTS**


**JULY
      31, 2007**




**1.
      REORGANIZATION TRANSACTIONS**





On
      August
      11, 2006, the Company performed a one for thirty reverse stock split, rounded
      up
      to the nearest whole share.





On
      September 7, 2006, the Company acquired Harbin Renhuang Pharmaceutical Company
      Limited, a Corporation incorporated under the laws of the British Virgin Island
      on January 18, 2006, (the “BVI”) including its 100% owned and only subsidiary,
      Harbin Renhuang Pharmaceutical Co. Ltd., incorporated under the laws of the
      People’s Republic of China on February 15, 2006 (“Renhuang China”) in
      exchange for issuing 29,750,000 shares of the Company's common stock, par value
      $0.001 per share (the “Common Stock”) to the BVI's stockholders, representing
      85% of the Company's capital stock on a fully diluted basis after taking into
      account the contemplated transaction. This transaction is referred to throughout
      this report as the “Merger”.





The
      Merger agreement was filed as Exhibit 10.1 to the Company's Current Report
      on
      Form 8-K filed with the Securities and Exchange Commission on August 29, 2006.
      The foregoing description of the Merger and the transactions contemplated
      thereby do not purport to be complete and are qualified in their entireties
      to
      the Merger agreement.





On
      August
      31, 2006, the Company's Board of Directors approved the Merger.





Upon
      closing of the Merger, BVI became a wholly owned subsidiary of the Company.
      After giving effect to the Merger and the rounding up of shares after reverse
      stock split on August 11, 2006, the Company had 35,000,181 common
      shares issued and outstanding and the former stockholders of BVI own
      approximately 85% of the issued and outstanding Common Stock of the Company.
      Accordingly, the Merger represented a change in control of the
      Company.





On
      May 1,
      2006, principal revenue producing activities in Harbin Renhuang Pharmaceuticals
      Stock Co., Ltd, the predecessor company, have been transferred to Renhuang
      China
      at the carrying amounts of the transferor.





On
      December 5, 2006, the Company’s Board of Directors approved a change in the
      Company’s fiscal year end from April 30 to October 31, effective with the
      Company’s Transitional Report on Form 10-K for the period ended as of October
      31, 2006.





For
      accounting purposes, the Merger has been accounted for as a recapitalization
      with the Company as the accounting acquiree and the BVI as the accounting
      acquirer. Upon effectiveness of the Merger, Renhuang China's business plan
      became the business plan of the Company.





On
      March
      3, 2007, the Company acquired all the assets and assumed a bank loan with
      accrued interest of Qingyang Extracting Factory, from Zhongfa Industrial Group
      Yerui Pharmaceutical Co., Ltd. for a total amount of RMB 3.7 million or
      approximately USD $480,000. The assets acquired included inventories, customer
      purchase orders, accounts receivables, corporate name, patents, trademarks,
      equipment, customer lists and records and other assets that are used or held
      for
      use in connection with Business of Qingyang Extracting Factory. The Company
      paid
      USD $310,000 in cash and assumed a bank loan with China Agriculture Bank in
      the
      principal amount of USD $140,000 and accrued interest of USD $30,000
      collateralized by the acquired assets. The transaction closed on March 3, 2007,
      and the Company has paid for the cash portion of the consideration USD $310,000
      (RMB 2,415,000).





8


**2.
      ORGANIZATION AND PRINCIPAL ACTIVITIES**





Renhuang
      Pharmaceuticals, Inc., (“Renhuang”) or the ("Company") was incorporated in the
      State of Nevada on August 18, 1988 as Solutions, Incorporated. Since that time,
      the Company has undergone a series of name changes as follows: Suarro
      Communications, Inc., e-Net Corporation, e-Net Financial Corp., e-Net.Com
      Corporation, e-Net Financial.Com Corporation, Anza Capital, Inc. and finally
      on
      July 28, 2006, the Company changed its name to Renhuang Pharmaceuticals,
      Inc.





On
      March
      3, 2006 the Company discontinued its operations and became a “shell”
company.


On
        September 7, 2006, the Company acquired Harbin Renhuang Pharmaceutical Company
        Limited, a Corporation incorporated under the laws of the British Virgin
        Island
        on January 18, 2006, (the “BVI”) including its 100% owned and only subsidiary,
        Harbin Renhuang Pharmaceutical Co., Ltd., incorporated under the laws of
        the
        People’s Republic of China on February 15, 20067 (“Renhuang China”) in exchange
        for issuing 29,750,000 shares of the Company’s common stock, par value $0.001
        per share (the “Common Stock”) to the BVI’s stockholders, representing 85% of
        the Company’s capital stock on a fully diluted basis after taking into account
        the contemplated transaction. This transaction is referred to throughout
        this
        report as the “Merger.”




Shares
      of
      the Company's Common Stock are trading on the NASD-Over the Counter (OTC)
      Bulletin Board Market under the symbol RHGP.





Unless
      otherwise provided in this current report, all references in this current report
      to “we”, “us”, “our company”, “our”, or the “Company” refer to Renhuang
      Pharmaceuticals, Inc.





The
      subsidiary company Harbin Renhuang Pharmaceuticals Co., Ltd (“the Subsidiary”)
      was incorporated at Harbin City in the People’s Republic of China (“the PRC” or
“China”) in 1996. The Subsidiary is principally engaged in production and sales
      of nutraceutical and bio-pharmaceutical products including tablets, drinks
      and
      health food. The subsidiary’s extensive sales network covers various provinces,
      cities, and counties throughout China.





The
      products are made in the two plant facilities located at Harbin City with
      specialized machinery under stringent cleanliness and hygienic
      processes.





The
      Company is subject to the consideration and risks of operating in the PRC.
      These
      include risks associated with the political and economic environment, foreign
      currency exchange and the legal system in the PRC.





The
      economy of PRC differs significantly from the economies of the “western”
industrialized nations in such respects as structure, level of development,
      gross national product, growth rate, capital reinvestment, resource allocation,
      self-sufficiency, rate of inflation and balance of payments position, among
      others. Only recently has the PRC government encouraged substantial private
      economic activities. The Chinese economy has experienced significant growth
      in
      the past several years, but such growth has been uneven among various sectors
      of
      the economy and geographic regions. Actions by the





PRC
      government to control inflation have significantly restrained economic expansion
      in the recent past. Similar actions by the PRC government in the future could
      have a significant adverse effect on economic conditions in PRC.





Many
      laws
      and regulations dealing with economic matters in general and foreign investment
      in particular have been enacted in the PRC. However, the PRC still does not
      have
      a comprehensive system of laws, and enforcement of existing laws may be
      uncertain and sporadic.





The
      Company’s operating assets and primary sources of income and cash flows are of
      interests in the PRC. The PRC economy has, for many years, been a
      centrally-planned economy, operating on the basis of annual, five-year and
      ten-year state plans adopted by central PRC governmental authorities, which
      set
      out national production and development targets. The PRC government has been
      pursuing economic reforms since it first adopted its “open-door” policy in 1978.
      There is no assurance that the PRC government will continue to pursue economic
      reforms or that there will not be any significant change in its economic or
      other policies, particularly in the event of any change in the political
      leadership of, or the political, economic or social conditions in, the PRC.
      There is no assurance that the Company will not be adversely affected by any
      such change in governmental policies or any unfavorable change in the political
      economic or social conditions, the laws or regulations, or the rate or method
      of
      taxation in the PRC.





9


As
      many
      of the economic reforms which have been or are being implemented by the PRC
      government are unprecedented or experimental, they may be subject to adjustment
      or refinement, which may have adverse effects on the Company. Further, through
      state plans and other economic and fiscal measures, it remains possible for
      the
      PRC government to exert significant influence on the PRC economy.





The
      Company’s financial instruments that are exposed to concentration of credit risk
      consist primarily of cash and cash equivalents, accounts receivable from
      customers and other receivables. Cash and cash equivalents are maintained with
      major banks in the PRC. The company and other public business activity is
      primarily with customers in the PRC.





Any
      devaluation of the Renminbi (RMB) against the United States dollar would
      consequently have adverse effects on the Company’s financial performance and
      asset values when measured in terms of the United States dollar. Should the
      RMB
      significantly devalue against the United States dollar, such devaluation could
      have a material adverse effect on the Company’s earnings and the foreign
      currency equivalent of such earnings. The Company does not hedge its RMB -
      United States dollar exchange rate exposure.





**3.
      BASIS OF PRESENTATION**





The
      consolidated financial statements are prepared in accordance with generally
      accepted accounting principles of the United States of America and include
      the
      financial statements of the Company and its wholly-owned subsidiary, Harbin
      Renhuang Pharmaceutical Company Limited and Harbin Renhuang Pharmaceutical
      Co.
      Ltd.





These
      consolidated financial statements should be read in conjunction with annual
      audited financial statements and the notes thereto included in the Company’s
      annual report on Form 10-KSB, and other reports filed with the SEC.





The
      accompanying unaudited interim financial statements reflect all adjustments
      of a
      normal and recurring nature which are, in the opinion of managements, necessary
      to present fairly the financial position, results of operations and cash flows
      of the Company for the interim periods presented. The results of operations
      for
      these periods are not necessarily comparable to, or indicative of, results
      of
      any other interim period or for the fiscal year taken as a whole.





**4.
      SUMMARY OF PRINCIPAL ACCOUNTING POLICIES**





**A.
      CASH AND CASH EQUIVALENTS**





The
      Company considers cash and cash equivalents to include cash on hand and demand
      deposits with banks with an original maturity of three months or less.





**B.
      ACCOUNTS RECEIVABLE**


Trade
      receivables are recognized and carried at the original invoice amount less
      allowance for any uncollectible amounts. An estimate for doubtful accounts
      is
      made when collection of the full amount is no longer probable. Bad debts are
      written off as incurred. An
      account is considered past due after ninety (90) days from the invoice
      date. The
      allowance on the doubtful accounts was $400,226 as at July 31,
      2007.





10


**C.
      INVENTORIES**





Inventories
      are stated at the lower of cost and net realizable value. Cost is calculated
      on
      the weighted average basis and includes all costs to acquire and other costs
      incurred in bringing the inventories to their present location and condition.
      The Company evaluates the net realizable value of its inventories on a regular
      basis and records a provision for loss, if material, to reduce the computed
      weighted average cost if it exceeds the net realizable value.





**D.
      PROPERTY, PLANT AND EQUIPMENT**





Property,
      plant and equipment are carried at cost. The cost of repairs and maintenance
      is
      expensed as incurred; major replacements and improvements are capitalized.





When
      assets are retired or disposed of, the cost and accumulated depreciation are
      removed from the accounts, and any resulting gains or losses are included in
      income in the year of disposition.





The
      Company recognizes depreciation of its property, plant and equipment on a
      straight-line basis over the estimated useful lives of the assets based on
      their
      costs less 5% residual value. The useful lives for property, plant and equipment
      are estimated as follows:





Buildings
            20
                yearsPlant
                and machinery
            10
                yearsOffice
                equipment and furnishings
            5
                to 10 yearsMotor
                vehicles
            5
                to 10 years





**E.
      FAIR VALUE OF FINANCIAL INSTRUMENTS**


The
      carrying value of financial instruments including cash, accounts receivables,
      other receivables, accounts payable, other payables and accrued expenses and
      debts, approximates their fair value at July 31, 2007 due to the relatively
      short-term nature of these instruments.





**F.
      CONSTRUCTION IN PROGRESS**


Construction
      in progress represents direct costs of construction or acquisition and design
      fees incurred. Capitalization of these costs ceases and the construction in
      progress is transferred to plant and equipment when substantially all the
      activities necessary to prepare the assets for their intended use are completed.
      No depreciation is provided until it is completed and ready for intended
      use.





**G.
      INCOME TAXES**





The
      Company accounts for income tax under the provisions of Statements of Financial
      Accounting Standards No. 109, which requires recognition of deferred tax assets
      and liabilities for the expected future tax consequences of events that have
      been included in the consolidated financial statements. Deferred income taxes
      are provided using the liability method. Under the liability method, deferred
      income taxes are recognized for all significant temporary differences between
      the tax and financial statement bases of assets and liabilities. In addition,
      the Company is required to record all deferred tax assets, including future
      tax
      benefits of capital losses carried forward, and to record a “valuation
      allowance” for any deferred tax assets where it is more likely than not that the
      asset will not be realized.





11


In
      accordance with the relevant income tax laws applicable to wholly foreign owned
      enterprises (WFOE) operating in PRC, the profits of the Company are fully exempt
      from income tax for two years (“tax holiday”), commencing from the first profit
      making year of operations, followed by a 50% exemption for the immediate next
      three years (“tax preferential period”), after which the profits of the Company
      will be taxable at the full rate, currently 33%.





Had
      this
      tax holiday not been available, income tax expense would have increased by
      approximately US $769,000 for the quarter ended July 31, 2007, and approximately
      US $2,895,832 for the nine months ended July 31, 2007.





**H.
      RELATED PARTIES**





Parties
      are considered to be related if one party has the ability, directly or
      indirectly, to control the other party or exercise significant influence over
      the other party in making financial and operational decisions. Parties are
      also
      considered to be related if they are subject to common control or common
      significant influence. Related parties may be individuals or corporate
      entities.





**I.
      IMPAIRMENT OF LONG-TERM ASSETS**





In
      accordance with the provisions of SFAS No. 144, “Accounting for the Impairment
      or Disposal of Long-Lived Assets”, the Company’s policy is to record an
      impairment loss against the balance of a long-lived asset in the period when
      it
      is determined that the carrying amount of the asset may not be recoverable.
      The
      determination is based on an evaluation of such factors as the occurrence of
      a
      significant event, a significant change in the environment in which the business
      assets operate or if the expected future non-discounted cash flows of the
      business was determined to be less than the carrying value of the assets. If
      impairment is deemed to exist, the assets will be written down to fair value.
      Management also evaluates events and circumstances to determine whether revised
      estimates of useful lives are warranted. As of July 31, 2007, management expects
      its long-lived assets to be fully recoverable.





**J.
      FOREIGN CURRENCY TRANSLATION**





Harbin
      Renhuang Pharmaceuticals Co., Ltd. maintains its books and accounting records
      in
      Renminbi ("RMB"), the PRC's currency, being the functional currency.





Foreign
      currency transactions in RMB are reflected using the temporal method. Under
      this
      method, all monetary items are translated into the functional currency at the
      rate of exchange prevailing at the balance sheet date. Non-monetary items are
      translated at historical rates. Income and expenses are translated at the rate
      in effect on the transaction dates. Transaction gains and losses if any, are
      included in the determination of net income (loss) for the period.





In
      translating the financial statements of the Company from its functional currency
      into its reporting currency in United States dollars, balance sheet accounts
      are
      translated using the closing exchange rate in effect at the balance sheet date
      and income and expense accounts are translated using an average exchange rate
      prevailing during the reporting period. Adjustments resulting from the
      transaction, if any, are included in accumulated other comprehensive income
      (loss) in stockholders’ equity.





The
      RMB
      is not freely convertible into foreign currency and all foreign exchange
      transactions must take place through authorized institutions. No representation
      is made that the RMB amounts could have been, or could be, converted into US$
      at
      the rates used in translation. The foreign exchange rate between the RMB and
      the
      United States dollar on July 31, 2007 and the average through May 1, 2007 to
      July 31, 2007 are:





12





Balance
                Sheet - Period end RMB : US$ exchange rate
            
            
            **7.5824**Operating
                Statement: Average quarterly RMB : US$ exchange rate
            
            
            **7.6385**





**K.
      USE OF ESTIMATES**





The
      preparation of financial statements in conformity with generally accepted
      accounting principles in the United States of America requires management to
      make estimates and assumptions that affect the reported amounts of assets and
      liabilities and disclosure of contingent assets and liabilities at the date
      of
      the financial statements, and the reported amounts of revenue and expenses
      during the reporting period. Significant estimates primarily related to the
      realizable value of accounts receivable, inventories, and the useful lives
      of
      plant and equipment. Actual results when ultimately realized could differ from
      those estimates.





**L.
      REVENUE RECOGNITION**





The
      Company recognizes revenue when the significant risks and rewards of ownership
      have transferred pursuant to PRC law, including factors such as when persuasive
      evidence of an arrangement exists, delivery has occurred, the sales price is
      fixed and determinable, and collectibility is reasonably assured. Renhuang
      generally recognizes products sales when the product is shipped. In the current
      period, no returns of any significance have occurred.





The
      Company provides a rebate to the distributors as an incentive plan. The rebate
      rate is setup for each product. When revenue is recognized, the revenue is
      reduced by the amount of rebate. On average, the rebate rate is 20% of gross
      revenue.





In
      accordance with the provisions of Staff Accounting Bulletin No. 104, revenue
      is
      recognized when merchandise is shipped, title passes to the customer and
      collectibility is reasonably assured.





**M.
      CONCENTRATION OF CREDIT RISK**





Financial
      instruments that potentially subject the Company to significant concentrations
      of credit risk consist primarily of trade accounts receivable. The Company
      performs ongoing credit evaluations with respect to the financial condition
      of
      its creditors, but does not require collateral. In order to determine the value
      of the Company's accounts receivable, the Company records a provision for
      doubtful accounts to cover probable credit losses. Management reviews and
      adjusts this allowance periodically based on historical experience and its
      evaluation of the collectibility of outstanding accounts receivable





**N.
      RESEARCH AND DEVELOPMENT**





Research
      and development costs are expensed as incurred. Engineers and technical staff
      are involved in the production of our products as well as on-going research,
      with no segregation of the portion of their salaries relating to research and
      development from the portion
      of their salaries relating to production. The total salaries are included in
      cost of sales. No research and development costs were incurred during this
      period.





**O.
      ADVERTISING**





Advertising
      costs consist primarily of promoting the Company and the Company’s products
      through printed advertisements in trade publications and television. Advertising
      costs are expensed as incurred. They are separately disclosed in income
      statements.





13


**P.
      CLASSIFICATION OF OPERATING COSTS AND EXPENSES**





The
      Company records its operating costs and expenses generally with the following
      classifications:





Cost
      of Goods Sold


Cost
      of
      goods sold consists primarily of raw materials, direct labor and manufacturing
      overhead. Manufacturing overhead includes an allocation of purchasing and
      receiving costs, inspection fees, warehousing utilities, supplies, factory
      and
      equipment repairs and maintenance, safety equipment and supplies, packing
      materials, and loading fees.





Selling
      Expenses


Selling
      expenses includes primarily of transportation and freight charges of delivering
      to customers, travel and entertainment, maintenance, payroll for sales staff,
      payroll taxes and benefits, advertising and promotion, telephone and utilities,
      insurance, sales commissions and exports fees.





General
      and Administrative Expenses


General
      and administrative expenses includes primarily of general office expenses,
      travel and entertainment, transportation, administrative payroll, payroll taxes
      and benefits, maintenance, telephone, utilities, printing, professional fees,
      continuing education, licenses and fees.





**Q.
      SEGMENTS**





No
      business segment analysis is provided for the quarter ended July 31, 2007,
      as no
      revenue and no income from operations is attributable to the segment other
      than
      sales of pharmaceutical products.





Further,
      no geographical segment analysis is provided for the quarter ended July 31,
      2007, as no revenue and no income from operations is attributable to the segment
      other than the Mainland China.





**R.
      EARNINGS PER SHARE**





The
      Company reports earnings per share in accordance with SFAS No. 128, “Earnings
      per Share.” Basic earnings per share are computed by dividing income available
      to common shareholders by the weighted average number of common shares
      available. Diluted earnings per share is computed similar to basic earnings
      per
      share except that the denominator is increased to include the number of
      additional common shares that would have been outstanding if the potential
      common shares had been issued and if the additional common shares were dilutive.





**S.
      COMPREHENSIVE INCOME**





The
      Company has adopted the provisions of Statement of Financial Accounting
      Standards No. 130, "Reporting Comprehensive Income" ("SFAS No. 130"). SFAS
      No.
      130 establishes standards for the reporting and display of comprehensive income,
      its components and accumulated balances in a full set of general-purpose
      financial statements. SFAS No. 130 defines comprehensive income to include
      all
      changes in equity except those resulting from investments by owners and
      distributions to owners, including adjustments to minimum pension liabilities,
      accumulated foreign currency translation, and unrealized gains or losses on
      marketable securities. In the current period, the only component of other
      comprehensive income is foreign translation gain of $318,591, which has been
      recorded as the accumulative other comprehensive income in the balance sheet.
      Consequently, the accumulated comprehensive income for the quarter and nine
      months ended July 31, 2007 was $2,332,318 and $9,116,150 respectively.





14


**T.
      RECENT PRONOUNCEMENTS**





In
      February 2006, the Financial Accounting Standards Board (“FASB”) issued
      Statement of Financial Accounting Standard (“SFAS”) No. 155, "Accounting for
      Certain Hybrid Financial Instruments - an amendment of FASB Statement No. 133
      and 140" (“SFAS 155”). SFAS 155 resolves issues addressed in Statement 133
      Implementation Issue No. D1, “Application of Statement 133 to Beneficial
      Interests in Securitized Financial Assets.” SFAS 155 is effective for all
      financial instruments acquired or issued after the beginning of the first fiscal
      year that begins after September 15, 2006. As such, the Company is required
      to
      adopt these provisions at the beginning of the fiscal year ended October 31,
      2007. The Company is currently evaluating the impact of SFAS 155 on its
      consolidated financial statements.





In
      March
      2006, the Financial Accounting Standards Board (“FASB”) issued Statement of
      Financial Accounting Standard (“SFAS”) No. 156, "Accounting for Servicing of
      Financial Assets - an amendment of FASB Statement No. 140" (“SFAS 156”). SFAS
      156 amends FASB Statement No. 140 with respect to the accounting for separately
      recognized servicing assets and servicing liabilities. SFAS 156 requires all
      separately recognized servicing assets and servicing liabilities to be initially
      measured at fair value, if practical. SFAS 156 is effective as of the beginning
      of the first fiscal year that begins after September 15, 2006. As such, the
      Company is required to adopt these provisions at the beginning of the fiscal
      year ended October 31, 2007. The Company is currently evaluating the impact
      of
      SFAS 156 on its consolidated financial statements.





In
      September 2006, the FASB issued Statement No. 158, "Employers' Accounting for
      Defined Benefit Pension and Other Postretirement Plans - An amendment of FASB
      Statements No. 87, 88, 106, and 132(R)" ("SFAS 158"). This Statement enhances
      disclosure regarding the funded status of an employer's defined benefit
      postretirement plan by (a) requiring companies to include the funding status
      in
      comprehensive income, (b) recognize transactions and events that affect the
      funded status in the financial statements in the year in which they occur,
      and
      (c) at a measurement date of the employer's fiscal year-end. Statement No.
      158
      effective for fiscal years ending after December 15, 2008, and is not expected
      to apply to the Company.




In
      February 2007, FASB issued SFAS No. 159, The Fair Value Option for Financial
      Assets and Financial Liabilities Including an Amendment of FASB Statement No.
      115 (" SFAS 159"). SFAS 159 permits entities to choose to measure many financial
      instruments and certain other items at fair values. SFAS 159 is effective for
      fiscal years after November 15, 2007. The Company is currently evaluating the
      impact of adopting SFAS 159 on our financial statements.





**5.
      ACCOUNTS RECEIVABLE**





The
      Company's accounts receivable as at July 31, 2007 are summarized as
      follows:


July
                31, 2007
            
            October
                31, 2006(Unaudited)
            
            (Audited)Accounts
                receivable
            
            $
            7,949,814
            
            $
            7,566,096Less:
                Allowance for doubtful accounts
            
            
            400,226Accounts
                receivable, net
            
            $
            7,549,588
            
            $
            7,566,096





The
      customers who owed over 10% in value of the total accounts receivable balance
      as
      at July 31, 2007 are listed as:


Customer
                  A:
              
              $
              1,190,407
              
              
              15
              %Customer
                  B:
              
              $
              891,257
              
              
              11
              %Customer
                  C:
              
              $
              791,483
              
              
              10
              %
  15


**6.
      INVENTORIES**





The
      Company's inventories as at July 31, 2007 are summarized as follows:





July
                31, 2007
            
            October
                31, 2006(Unaudited)
            
            (Audited)Raw
                materials
            
            $
            1,336,941
            
            $
            569,349Finished
                goods
            
            
            170,102
            
            
            52,795$
            1,507,043
            
            $
            622,144





Raw
      material is mainly comprised of Chinese herbs, herbal related ingredients and
      packing materials, and they were for manufacturing the products such as tablets
      and drinks.





The
      Company does not have obsolete inventories as of July 31, 2007 and October
      31,
      2006.





**7.
      PROPERTY, PLANT AND EQUIPMENT**





July
                31, 2007
            
            October
                31, 2006(Unaudited)
            
            (Audited)**Cost:-**Plant
                and machinery
            
            $
            2,898,834
            
            $
            2,718,407Office
                equipment and furnishings
            
            
            29,685
            
            
            3,966Building
            
            
            219,456Motor
                vehicles
            
            
            35,458
            
            
            19,6723,183,433
            
            
            2,742,045**Less:
                Accumulated depreciation:-**Plant
                and machinery
            
            
            348,177
            
            
            131,405Office
                equipment and furnishings
            
            
            946
            
            
            44Building
            
            
            3,475Motor
                vehicles
            
            
            2,137
            
            
            311354,735
            
            
            131,760**Net
                value**
            
            $
            2,828,698
            
            $
            2,610,285





Depreciation
      expenses relating to property, plant and equipment were $75,205 for the quarter
      ended July 31, 2007, and $213,680 for the nine months ended July 31, 2007.





**8.
      CONSTRUCTION IN PROGRESS**





The
      balance of construction in progress $474,784 (RMB 3.6 million) related to the
      assets purchase from Qing Yang Extracting Factory closed at March 3, 2007.
      These
      assets have not been used until the inspection and further construction are
      expected to be completed at the end of 2007. The transfer of title is in
      process.





**9.
      DEFERRED EXPENSES**





The
      deferred expenses are related to the cost of fund raising, which is disclosed
      in
      Note 20 subsequent event.





16


**10.
      SHORT TERM LOAN**





The
      short
      term loan agreement was entered with a third party as a short term investment.
      The loan was unsecured, was initiated on July 30, 2007 and was returned by
      August 2007, with the annual interest rate being 7.2%.





**11.
      ACCOUNTS PAYABLES AND ACCRUALS**





The
      balances over 10% of the total balance as at July 31, 2007 are made up of
      $174,087, $94,872, and $67,225, which accounted for 30%, 18%, and 13% of the
      total balance respectively.





The
      balance as at October 31, 2006 includes $419,901 payable to a related party
      on
      the purchase of plant raw materials, which accounted for 66% of the total
      payable balance. Another account payable balance over 10% is $93,664, or 15%
      of
      the total payable balance.





The
      suppliers from whom the purchased amount is over 10% of the total purchase
      for
      the three months ended July 31, 2007 are listed as:


Supplier
                  A:
              
              $
              515,807
              
              
              21
              %Supplier
                  B:
              
              $
              267,417
              
              
              11
              %





**12.
      OTHER PAYABLES**


The
        balance as at July 31, 2007 includes professional fee payable $307,500, sales
        rebate payable of $1,017,305, payroll payable of $35,000, VAT payable of
        $53,213, social insurance payable of $255,975, and accrual of employee training
        for $6,236.
 
 As
        at
        October 31, 2006, the balance includes sales, rebate payable of $1,031,101,
        VAT
        payable of $419,121, professional fee payable of $302,500 and payroll payable
        of
        $124,320.


**13.
      COMMON STOCK**


During
        the nine months period ended July 31, 2007, 96,500 common stocks were issued
        as
        S8 shares for $284,675.





**14.
      INCOME TAXES**





The
      Company is subject to state and local income taxes within the PRC at the
      applicable tax rate as reported in their PRC statutory financial statements
      in
      accordance with the relevant income tax laws.





For
      the
      years of 2006 and 2007, the Company was granted tax holiday and concession
      and
      is entitled to full exemption from corporation income taxes up to December
      2007.
      From 2008 onwards, the Company also receives a special income tax rate of 15%
      as
      it is wholly foreign owned company where there is tax exemption for certain
      enterprises.





**15.
      RESERVES**





The
      reserve funds at July 31, 2007 are comprised of the following:





July
                31, 2007
            
            October
                31, 2006(Unaudited)
            
            (Audited)Statutory
                surplus reserve fund
            
            $
            1,367,793
            
            $
            564,756Public
                welfare fund
            
            
            683,896
            
            
            282,377$
            2,051,689
            
            $
            847,133




17


Pursuant
      to the relevant laws and regulations of the PRC, the profits of the Company,
      which are based on their PRC statutory financial statements, are available
      for
      distribution in the form of cash dividends after they have satisfied all the
      PRC
      tax liabilities, provided for losses of previous years, and made appropriations
      to reserve funds, as determined by the Board of Directors in accordance with
      the
      PRC accounting standards and regulations.





As
      stipulated by the relevant laws and regulations for enterprises operating in
      the
      PRC, companies are required to make annual appropriations to two reserve funds,
      consisting of the statutory surplus and public welfare funds. In accordance
      with
      the relevant PRC regulations and the articles of association of the respective
      companies, the companies are required to allocate a percentage of their profits
      after taxation, as determined in accordance with the PRC accounting standards
      applicable to the companies, to the statutory surplus reserve until such reserve
      reaches 50% of the registered capital of the companies.





Net
      income as reported in the US GAAP financial statements differs from that as
      reported in the PRC statutory financial statements. In accordance with the
      relevant laws and regulations in the PRC, the profits available for distribution
      are based on the statutory financial statements. If the Company has foreign
      currency available after meeting its operational needs, it may make its profit
      distributions in foreign currency to the extent foreign currency is available.
      Otherwise, it is necessary to obtain approval and convert such distributions
      at
      an authorized bank.





**16.
      WARRANTS**


At
        July
        31, 2007 (Unaudited), the following table summarizes the changes in warrants
        outstanding and the related prices for the shares of the company’s common stock
        issued to non-employees of the company. These warrants were granted in lieu
        of
        cash for compensation for services performed of a newly appointed director.
        The
        company is obligated to grant 10,000 warrants on July 31 for three consecutive
        years, starting from July 31, 2007.


Warrants
                  Outstanding
              
              Warrants
                  ExercisableExercise
                  Prices
              
              Number
                  Outstanding
              
              Weighted
                  Average Remaining Contractual Life (years)
                2.71
              
              Weighted
                  Average Exercise Price
              
              Number
                  Exercisable
              
              Weighted
                  Average Remaining Contractual Life (years)$3.02
              
              
              15,000
              
              
              2.71
              
              $
              3.02
              
              
              15,000
              
              
              2.71$2.50
              
              
              10,000
              
              
              3.00
              
              $
              2.50
              
              
              10,000
              
              
              3.00





Transactions
      involving warrants are summarized as follows:


Number
                of Shares
            
            Weighted
                Average Price Per ShareOutstanding
                at October 31, 2006
            
            
            --
            
            
            --Granted---
                April 16, 2007
            
            
            15,000
            
            $
            3.02---
                July 31, 2007
            
            
            10,000
            
            $
            2.50Exercised
            
            
            --
            
            
            --Cancelled
                or expired
            
            
            --
            
            
            --Outstanding
                at July 31, 2007
            
            
            25,000
            
            $
            2.81




18




The
      estimated value of the compensatory warrants granted to Director in exchange
      for
      services was determined using the Black-Scholes pricing model and the following
      assumptions:





15,000
                warrants granted on April 16, 2007
            
            10,000
                warrants granted on July 31, 2007Significant
                assumptions (weighted-average)Risk-free
                interest rate at grant date
            
            
            4.74
            %
            
            4.78
            %Expected
                stock price volatility
            
            
            70.83
            %
            
            48.59
            %Expected
                dividend payoutExpected
                option life-years (a)
            
            
            3
            
            
            3





The
      Company entered into a Director appointment agreement with Mr. Magnus Moliteus
      dated April 16, 2007, pursuant to which the Company issued Mr. Magnus Moliteus
      15,000 warrants, which terminates on April 16, 2010, to purchase 15,000 shares
      of Renhuang’s common stock at $3.02 per share. On July 31, 2007, 10,000 warrants
      were issued to Mr. Magnus Moliteus. The Company valued the warrants using the
      Black-Scholes calculation model, and the warrants were deemed to have a value
      of
      $22,442 and $9,257 respectively. These amounts were charged to expense on the
      Company’s financial statements for the three months and nine months ended July
      31, 2007 (Unaudited)





**17.
      RELATED PARTY TRANSACTIONS**





The
      Company had the following significant related party transactions during the
      period:





n
            The
                Company rented property and plant from its predecessor Harbin Renhuang
                Pharmaceutical Stock Co. Ltd. The lease term is from May 1, 2007
                to May 1,
                2008, with monthly rental payment of $46,160. The rental is fair
                value as
                appraised by a third party property company.





**18.
      COMMITMENTS AND CONTINGENCIES**





**A.
      CAPITAL AND LEASE COMMITMENTS**





As
      of
      July 31, 2007, the Company has the following significant capital and lease
      commitments outstanding: **





The
      Company rented office from Hei Long Jiang Jiu San You Zhi Co., Ltd.  The
      lease
      term is from May 1, 2007 to April 30, 2010, with total rental payment $328,337.





The
      company rented plant from its predecessor Harbin Renhuang Pharmaceutical Stock
      Co. Ltd., see Note 17.


July
                  31, 2007(Unaudited)within
                  1 year
              
              $
              660,7411-2
                  years
              
              
              291,4642-3
                  years
              
              
              106,826Total
              
              $
              1,059,031




19


**B.
      LEGAL PROCEEDINGS**





The
      Company is not currently involved in any litigation. There is no action, suit,
      proceeding, inquiry or investigation before or by any court, public board,
      government agency, self-regulatory organization or body pending or, to the
      knowledge of the executive officers of the Company.





**19.
      CURRENT VULNERABILITY DUE TO CERTAIN CONCENTRATIONS**





The
      Company faces a number of risks and challenges since its operations are in
      the
      PRC. The Company's operations in the PRC are subject to special considerations
      and significant risks not typically associated with companies in North America
      and Western Europe. The Company's results may be adversely affected by changes
      in the political and social conditions in the PRC, and by changes in
      governmental policies with respect to laws and regulations, anti-inflationary
      measures, currency conversion and remittance abroad, and rates and methods
      of
      taxation, among other things.





**20.
      SUBSEQUENT EVENT**





As
      further described in Note 1, Renhuang Pharmaceuticals, Inc., consummated a
      Reverse Merger on September 7, 2006. As a continuation thereof, the Company
      is
      currently in negotiations with various investors regarding financing up to
      $20
      million dollars and it is anticipated that the Company will consummate a finance
      transaction with one or more of them in the near future.





**21.
      COMPARATIVE FINANCIAL INFORMATION**





As
      discussed in Note 1- Reorganization Transactions, the Company acquired Harbin
      Renhuang Pharmaceutical Company Limited and its wholly owned subsidiary, Harbin
      Renhuang Pharmaceutical Co., Ltd.


For
        information purposes, we present below the results of operations of Harbin
        Renhuang Pharmaceutical Stock Co. Ltd. (“Old Renhuang”) for the six months ended
        April 31, 2006 and the cash flow statement for the six months ended April
        31,
        2006.





20


**HARBIN
      RENHUANG PHARMACEUTICAL STOCK CO., LTD**


**(INCORPORATED
      IN THE PRC)**





**STATEMENTS
      OF INCOME**


**FOR
      THE SIX MONTHS ENDED APRIL 30, 2006**





**(Unaudited)****Six
                Months**
              **Ended**
              **April
                30,**
              **2006**SALES
            
            $
            16,427,921COST
                OF SALES
            
            
            8,863,227GROSS
                PROFIT
            
            
            7,564,694SELLING
                AND DISTRIBUTION EXPENSES
            
            
            577,370ADVERTISING
            
            
            2,917,988GENERAL
                AND ADMINISTRATIVE EXPENSES
            
            
            1,632,290PROVISION
                FOR DOUBTFUL ACCOUNTS
            
            
            622,618DEPRECIATION
                AND AMORTIZATION
            
            
            328,051RESEARCH
                AND DEVELOPMENT
            
            
            817,547INCOME
                FROM OPERATIONS
            
            
            668,830FINANCE
                COSTS
            
            
            359,465GOVERNMENT
                SUBSIDIES
            
            
            (155,316
            )OTHER
                EXPENSES
            
            
            6,781INCOME
                BEFORE INCOME TAXES
            
            
            457,900INCOME
                TAXES
            
            
            --NET
                INCOME ATTRIBUTABLE TOSHAREHOLDERS
            
            $
            457,900





21





**HARBIN
      RENHUANG PHARMACEUTICAL STOCK CO., LTD**


**(INCORPORATED
      IN THE PRC)**





**STATEMENTS
      OF CASH FLOW**


**FOR
      THE SIX MONTHS ENDED APRIL 30, 2006**





**(Unaudited)****2006****CASH
                FLOWS FROM OPERATING ACTIVITIES:**Net
                income
            
            $
            457,900Adjustments
                to reconcile net income to net cash fromoperating
                activities :Depreciation
                and amortization
            
            
            328,051Changes
                in operating assets and liabilities:Trade
                receivables, net
            
            
            (1,327,585
            )Inventories
            
            
            1,111,003Prepayments
            
            
            (506,399
            )Other
                receivables, net
            
            
            (116,993
            )Deferred
                expenses
            
            
            (694,211
            )Accounts
                payable and accruals
            
            
            (180,641
            )Advance
                from customers
            
            
            228,219Other
                payables
            
            
            203,108**NET
                CASH FROM OPERATING ACTIVITIES**
            
            
            (497,548
            )**CASH
                FLOWS FROM INVESTING ACTIVITIES:**Acquisition
                of property, plant and equipment
            
            
            (1,876,244
            )Disposition
                of property, plant and equipment
            
            
            2,739,663**NET
                CASH FROM IN INVESTING ACTIVITIES**
            
            $
            863,419




22





**HARBIN
      RENHUANG PHARMACEUTICAL STOCK CO., LTD**


**(INCORPORATED
      IN THE PRC)**





**STATEMENTS
      OF CASH FLOW (CONTINUED)**


**FOR
      THE SIX MONTHS ENDED APRIL 30, 2006**





**(Unaudited)****2006****CASH
                FLOWS FROM FINANCING ACTIVITIES:**Due
                (to)/from a director
            
            $
            (916,165
            )Due
                to related parties, net
            
            
            (278,050
            )Dividend
                payable
            
            
            --Repayment
                of bank loan, net
            
            
            (482,398
            )**NET
                CASH FROM FINANCING ACTIVITIES**
            
            
            (1,676,613
            )**NET
                CHANGE IN CASH AND CASH EQUIVALENTS**
            
            
            (1,310,742
            )EFFECT
                OF EXCHANGE RATE CHANGES ON CASH AND CASHEQUIVALENTS
            
            
            97,235Cash
                and cash equivalents, beginning of period
            
            
            3,439,402Cash
                and cash equivalents, end of period
            
            $
            2,225,895**SUPPLEMENTARY
                CASH FLOW DISCLOSURES**Interest
                paid
            
            $
            245,145Income
                taxes paid
            
            $
            --







23




**ITEM
      2**  **Managements
      Discussion and Analysis of Financial Conditi** **on
      and Results of Operations.**





**Overview**





The
      following discussion of the financial condition and results of operation of
      Renhuang Pharmaceuticals, Inc. should be read in conjunction with the financial
      statements and the notes to those statements included in this Quarterly Report
      on Form 10-Q. This discussion includes forward-looking statements that involve
      risk and uncertainties. As a result of many factors, actual results may
      differ materially from those anticipated in the forward-looking
      statements.




As
      of
      March 3, 2006 we discontinued our previous operations as a company specializing
      in the providing of home financing through the brokerage of residential home
      loans. On September 7 ,
      2006,
      we acquired 100% of the issued and outstanding shares of Harbin Renhuang
      Pharmaceutical Company Limited, a corporation incorporated under the laws of
      the
      British Virgin Islands, (“BVI’’), whose only assets are 100% of Harbin Renhuang
      Pharmaceutical Co. Ltd., incorporated under the laws of the People’s Republic of
      China (“Renhuang China”) mainly focused on the research, production and sales of
      traditional Chinese and Western medical and bio-pharmaceutical products in
      China.





On
      May 1,
      2006, Harbin Renhuang Pharmaceutical Stock Co. Ltd., (“Old Renhuang”)
      transferred the majority of its operating assets to Renhuang China, with the
      exception of the buildings Old Renhuang owns (including where we rent our office
      space and production facilities), and Old Renhuang’s account receivables,
      inventories and other assets with zero or insignificant value. The principal
      business activities of Renhuang remained unchanged. On March 3, 2006, Renhuang
      Medicine for Animals Co. Ltd. a company controlled by our President and Chief
      Executive Officer, Mr. Li Shaoming, invested 25 million RMB (about US $3.3
      million) in cash in Renhuang China.





Our
      pharmaceutical products are distributed through more than 60 sales offices
      with
      more than 2,000 commission-based sales people. Upon the effectiveness of the
      Merger, we adopted the business of Renhuang China, which we have continued
      as
      our sole line of business.





Upon
      closing of the Merger, BVI and its subsidiary Renhuang China
      became our wholly owned subsidiaries. The Former stockholders of BVI own
      approximately 85% of our issued and outstanding common stock.





Since
      we
      will operate Renhuang China as our sole line of business,
      the analysis of the pro forma financial statements for the three
      months and nine months ended on July 31, 2006 is the operation of Harbin
      Renhuang Pharmaceutical Co, Ltd. (Renhuang China).





**Reverse
      Merger**




Our
      acquisition of the BVI company and its subsidiary Renhuang China was
      accounted for as a reverse merger, because, after giving effect to the
      share exchanges, the former stockholders of BVI hold a majority of our
      outstanding common stock on a voting and fully diluted basis. As a result of
      the
      share exchanges, Renhuang was deemed to be the acquirer for accounting purposes.
      Accordingly, the financial statements presented are those of Renhuang China
      for
      all periods prior to our acquisition of the BVI company on September 7, 2006,
      and the financial statements of the consolidated companies from the acquisition
      date forward. Since BVI was not formed until May 1, 2006, we have included
      the
      three months ended July 31, 2006 financial information for the statement of
      income and statement of cash flows, while the previous six months, ended April
      30, 2006, prior to the formation of BVI, have been included in the notes to
      the
      financial statements (Note 21). Therefore, the nine-month numbers include in
      the
      management’s discussion and analysis section are calculated by adding the
      figures for the three months ended July 31, 2006 contained in the financial
      statements with the figures for Old Renhuang for the six months ended April
      30,
      2006, contained in Note 21.





24


**Change
      in Fiscal Year**





On
      December 5, 2006, our Board of Directors approved the change of our fiscal
      year end from April 30 to October 31. As a result we filed a Transitional
      Report for the six months ended October 31, 2006 on Form 10-K. For Old
      Renhuang’s three month comparative numbers for the same period in 2006, see
      Note 21 to the financial statements filed attached hereto. For our numbers
      from the same period one year ago (when we were Anza Capital, Inc.) please
      see
      our Quarterly Report on Form 10-Q for the three months ended April 30,
      2006.





Since
      the
      change in our fiscal year occurred in conjunction with our shift from a shell
      company to a company specializing in the research, production and sales of
      traditional Chinese and Western medical and bio-pharmaceutical products in
      China
      our previous operations are not relevant to our current operations and our
      previous operations are covered in our previous Quarterly Reports on Form 10-Q,
      therefore, this discussion focuses on the three month and nine months ended
      July
      31, 2007 and a comparison with the financial information consisting of results
      of operation of the Company for the period from May 1, 2006 to July 31, 2006,
      and results of operations of Old Renhuang from the period from November 1,
      2005
      to April 30, 2006 (“Combined Renhuang”).





**Assets
      Acquisition**





On
      March
      3, 2007, we acquired all the assets and assumed a bank loan with accrued
      interest of Qingyang Extracting Factory, from Zhongfa Industrial Group Yerui
      Pharmaceutical Co., Ltd. for a total amount of RMB 3.7 million or approximately
      USD $480,000. The assets acquired included inventories, customer purchase
      orders, accounts receivables, corporate name, patents, trademarks, equipment,
      customer lists and records and other assets that are used or held for use in
      connection with Business of Qingyang Extracting Factory. We paid USD $310,000
      in
      cash and assumed a bank loan with China Agriculture Bank in the principal amount
      of USD $140,000 and accrued interest of USD $30,000 collateralized by the
      acquired assets. The transaction closed on March 3, 2007, and we have paid
      for
      the cash portion of the consideration USD $310,000 (RMB 2,415,000).





**Three
      Months Ended July 31, 2007 Compared to Three Months Ended July 31,
      2006**




**Introduction**




For
      the
      three months ended July 31, 2007, we generated $5,071,331 in revenues on cost
      of
      sales of $2,491,963. With these revenues and cost of sales for the three months
      ended July 31, 2007, we had a net income from operations and a net income
      attributable to shareholders of $ 2,013,727 .
      As
      noted above, we acquired the majority of our current operations from Old
      Renhuang. For the three months ended July 31, 2006, we had revenues of
      $ 5,413,875 ,
      on cost
      of sales of $ 2,359,503 .
      With
      these revenues and costs of sales we had net income of $2,622,015.





25





**Revenues,
      Expenses and Profit from Operations**







**Three
                Months**
              **Ended**
              **July
                31, 2007**
            
            **Three
                Months**
              **Ended**
              **July
                31, 2006**Revenue
            
            $
            5,071,331
            
            $
            5,413,875Cost
                of Sales
            
            
            (2,491,963
            )
            
            (2,359,503
            )Selling
                and Distribution Expenses
            
            
            (12,178
            )
            
            (87,997
            )Advertising
                Expenses
            
            
            (7,588
            )
            
            --General
                and Administrative Expenses
            
            
            (655,929
            )
            
            (287,696
            )Research
                and Development
            
            
            --
            
            
            --(Provision
                for Doubtful Accounts)/Recovery
            
            
            178,040
            
            
            (18,793
            )Depreciation
                and Amortization
            
            
            (75,205
            )
            
            (42,851
            )Other
                Income/(Expenses)
            
            
            7,219
            
            
            4,980Net
                Income
            
            $
            2,013,727
            
            $
            2,622,015




*Revenues*





Our
      revenues of $5,071,331 decreased by 6% when compared to our revenues from the
      same period one year ago of $5,413,875. Our revenues for the three months ended
      July 31, 2007 consisted primarily of sales of the following products:
      Acanthopanax products, Shark Power Health Care products, and other Chinese
      traditional medical products. The value percentage on the sales of those
      products are 53%, 16% and 31%, respectively.





*Cost
      of Sales*





Our
      cost
      of sales for the three months ended July 31, 2007 were $2,491,963, representing
      50% of revenue and consisted primarily of raw material, labor and production
      costs, compared to our cost of sales for the same period one year ago of
      $2,359,503, representing approximately 43% of sales in that period. The slight
      decrease in our percentage of costs to revenues is primarily attributable to
      the
      fact we are putting more focus on our Acanthopanax products. As a result, the
      sales of certain high gross profit products, such as Shark Power Health Care
      products, are decreasing. This shift of focus to our Acanthopanax products
      is
      being made because our management believes there is higher future market
      potential for the Acanthopanax products over our Shark Power Health Care
      products. Costs allocated to the aforementioned products, Acanthopanax products,
      Shark Power Health Care products, and other Chinese traditional medical products
      are 49%, 5% and 46% respectively.





*Selling
      and Distribution Expenses*





Our
      selling and distribution expenses are those expenses we have related to the
      actual sales of our products and the costs we incur in distributing those
      products. For the three-month period ended July 31, 2007, our selling and
      distribution expenses were $12,178, decreased by $75,819 or 86% from Old
      Renhuang’s selling and distribution expenses of $87,997, for the same period one
      year ago largely due to lower entertainment expense and traveling expense with
      improved management of marketing channels.





26


*Advertising
      Expenses*


For
        the
        three months ended July 31, 2007, we had advertising expenses of $7,588.
        These
        advertising expenses were primarily related to the advertising of Acanthopanax.
        Our advertising expenses were zero for the same period one year ago.
 
 *General
        and Administrative Expenses*
 
 Our
        general and administrative expenses were $655,929 for the three-month period
        ended July 31, 2007, compared to $287,696 during the same period one year
        ago. The decrease is due mainly to the decrease of inventory obsolescence
        as a
        result of more efficient inventory management. Of our current $655,929 general
        and administrative expenses, the primary expenses were as follows: $284,675
        for
        professional fee, $102,406 for payroll, and $55,824 for accrual of social
        insurance.
 
 *Depreciation
        and Amortization*
 
 We
        had
        depreciation and amortization expenses of $75,205 for the three months ended
        July 31, 2007, which related to property, plant and equipment. This is compared
        to $ 42,851 for the
        Company for the same period one year ago. The reason for our higher depreciation
        and amortization in the quarter ended July 31, 2007 is that we made an
        acquisition that quarter, and with more building and producing facilities
        being
        added to our assets, we generated more depreciation and
        amortization.
 
 *Provision
        for Doubtful Accounts/Recovery*
 
 Recovery
        of doubtful accounts for the three months ended July 31, 2007 was $178,040,
        compared to a provision for doubtful accounts of zero for the same period
        last
        year. We had a provision for doubtful accounts/recovery for the three months
        ended July 31, 2006 because Renhuang China started to operate on May 1, 2006,
        and, therefore, there is no doubtful accounts/recovery for sales less than
        90
        days.
 
 *Net
        Income (Loss) from Operations*
 
 Our
        net
        income for the three months ended July 31, 2007, was $2,013,727, while Old
        Renhuang’s net income for during the same period one year ago was $2,622,015.
        These figures are fairly indicative of our expected net income for future
        three
        month periods ended July 31, 2007.
 
 **Nine
        Months Ended July 31, 2007 Compared to Nine Months Ended July 31,
        2006**
 
 **Introduction**
  For
        the
        nine months ended July 31, 2007, we generated $20,890,656 in revenues on
        cost of
        sales of $10,184,980. With these revenues and cost of sales for the nine
        months
        ended July 31, 2007, we had a net income from operations and a net income
        attributable to shareholders of $8,458,873. As noted above, we acquired the
        majority of our current operations from Combined Renhuang. For the nine months
        ended July 31, 2006, Combined Renhuang had revenues of $21,841,797, on cost
        of
        sales of $11,222,730. With these revenues and costs of sales Old Renhuang
        had a
        net income of $3,079,915 for the same period one year ago.




27


**Revenues,
        Expenses and Profit from Operations**


**Nine
                  Months**
                **Ended**
                **July
                  31, 2007**
              
              **Nine
                  Months**
                **Ended**
                **July
                  31, 2006**
                **(Combined
                  Renhuang)**Revenue
              
              $
              20,890,656
              
              $
              21,841,797Cost
                  of Sales
              
              
              (10,184,980
              )
              
              (11,222,730
              )Selling
                  and Distribution Expenses
              
              
              (134,624
              )
              
              (665,368
              )Advertising
                  Expenses
              
              
              (180,269
              )
              
              (2,917,988
              )General
                  and Administrative Expenses
              
              
              (1,292,433
              )
              
              (1,919,986
              )(Provision
                  for Doubtful Accounts)/Recovery
              
              
              (443,082
              )
              
              (641,411
              )Depreciation
                  and Amortization
              
              
              (213,680
              )
              
              (370,902
              )Government
                  Subsidy
              
              
              --
              
              
              155,316Research
                  and Development
              
              
              --
              
              
              (817,547
              )Other
                  Income/(Expenses)
              
              
              17,285
              
              
              (361,266
              )Net
                  Income
              
              $
              8,458,873
              
              $
              3,079,915


*Revenues*
 
 Our
        revenues of $20,890,656 decreased by approximately $951,141 or 4% when compared
        to Combined Renhuang’s revenues from the same period one year ago of
        $21,841,797. Our revenues for the nine months ended July 31, 2007 consisted
        primarily of sales of the following products: Acanthopanax products, Shark
        Power
        Health Care products, and other Chinese traditional medical products.
 
 *Cost
        of Sales*
 
 Our
        cost
        of sales for the nine months ended July 31, 2007, were $10,184,980, representing
        49% of revenue and consisted primarily of raw material, labor and production
        costs, compared to Combined Renhuang’s cost of sales for the same period one
        year ago of $11,222,730, representing approximately 51% of sales in that
        period.
        The decrease in the percentage of cost to revenue is due to the economy of
        scales resulted from the reduction of the production and sales.
 
 *Selling
        and Distribution Expenses*
 
 Our
        selling and distribution expenses are those expenses we have related to the
        actual sales of our products and the costs we incur in distributing those
        products. For the nine-month period ended July 31, 2007, our selling and
        distribution expenses were $134,624, decreased by $530,744 or 80% from Combined
        Renhuang’s selling and distribution expenses of $665,368, for the same period
        one year ago largely due to improved management of marketing channels and
        cost
        controls.
 
 *Advertising
        Expenses*
 
 For
        the
        nine months ended July 31, 2007, we had advertising expenses of $180,269.
        These
        advertising expenses were primarily related to the advertising of Acanthopanax.
        Combined Renhuang’s advertising expenses were $2,917,988 for the same period one
        year ago. This significant decrease was due to the fact Combined Renhuang
        had a
        more aggressive advertising strategy a year ago in order to increase name
        recognition in the South of China.





28


*General
      and Administrative Expenses*


Our
        general and administrative expenses were $1,292,433 for the nine-month period
        ended July 31, 2007, compared to $1,938,779 during the same period one year
        ago for Combined Renhuang, largely due to the decrease of inventory
        obsolescence, traveling expense and office expense.
 
 *Provision
        for Doubtful Accounts/Recovery*
 
 Provision
        for doubtful accounts for the nine months ended July 31, 2007 was $443,082,
        comparable to $641,411 for the same period last year. The amount from nine
        months ended July 31, 2006, was all generated from Old Renhuang before May
        1,
        2006. With improvements in our collections for the nine months ended July
        31,
        2007, we were ale to decrease our provision for doubtful accounts/recovery
        for
        this period.
 
 *Depreciation
        and Amortization*
 
 We
        had
        depreciation and amortization expenses of $213,680 for the nine months from
        ended July 31, 2007, which related to property, plant and equipment. This
        is
        compared to $370,902 for Combined Renhuang for the same period one year ago,
        which included depreciation on buildings that were not transferred to the
        Company.
 
 *Net
        Income (Loss) from Operations*
 
 Our
        net
        income for the nine months ended July 31, 2007, was $8,458,873, which increased
        by over 64% when compared to $3,079,915 for Combined Renhuang for the same
        period one year ago. This significant improvement in net income over Combined
        Renhuang for the same period one year ago is primarily due to significant
        decreases in cost of sales and various expenses.
 
 *Liquidity
        and Capital Resources*
  **Introduction**
  Our
        cash,
        current assets, total assets, current liabilities, and total liabilities
        as of
        July 31, 2007 and 2006, respectively, are as follows:


July
                  31, 2007
              
              July
                  31, 2006Cash
                  and Cash Equivalents
              
              $
              53,660
              
              $
              2,227,048Total
                  Current Assets
              
              
              19,012,704
              
              
              7,474,143Total
                  Assets
              
              
              22,316,186
              
              
              10,988,894Total
                  Current Liabilities
              
              
              2,258,887
              
              
              1,195,868Total
                  Liabilities
              
              $
              2,258,887
              
              $
              1,195,868


Sources
      and Uses of Cash





*Operations*





Net
      cash
      generated from operating activities was $8,361,831 for the nine months ended
      July 31, 2007, compared to net cash used in operating activities of $(1,883,611)
      for Combined Renhuang for the nine months ended July 31, 2006. Our net cash
      used
      in operating activities for the current nine month period was primarily $16,508
      in net trade receivables, $( 884,889 )
      in
      inventories, $982,113 from other net receivables, ($419,910) in total related
      party accounts payable and accruals, $45,709 in third party accounts payable
      and
      accruals, and ($201,813) in other payables.





29


*Investments*





Net
      cash
      used in investing activities was $(9,996,010) for the nine months ended July
      31,
      2007, compared to net cash generated from investing activities of $887,493
      for
      Combined Renhuang for the same period one year ago. For the nine months ended
      July 31, 2007, our cash used in investing activities related to a short
      term loan $(9,495,674), the acquisition of property, plant and equipment in
      the
      amount of $(114,058) and construction in progress in the amount of
      $(386,278).





*Financing*





Net
      cash
      from financing activities was $0 for the nine months ended July 31, 2007,
      compared to net cash used in financing activities in the amount of $ (1,676,613) for
      Combined Renhuang for the nine months ended July 31, 2006. The contributors
      to
      the cash used in financing activities during nine months ended July 31, 2006
      included repayment of bank loans for $(482,398), payable to related parties
      of
      $(278,050), and payable to a director of $(916,165).





Debt
      Instruments, Guarantees, and Related Covenants





The
      Company does not have any long term debt and short term debt, and has not
      entered into any guarantee arrangements or other related covenants.





**Critical
      Accounting Policies**





The
      preparation of our financial statements in conformity with accounting principles
      generally accepted in the United States of America requires our management
      to
      make certain estimates and assumptions that affect the reported amounts of
      assets and liabilities and disclosure of contingent assets and liabilities
      at
      the date of the financial statements and the reported amounts of revenues and
      expenses during the reporting period. As such, in accordance with the use of
      accounting principles generally accepted in the United States of America, our
      actual realized results may differ from management’s initial estimates as
      reported. A summary of our significant accounting policies are located in the
      notes to the financial statements which are an integral component of this
      filing.





**Off-balance
      Sheet Arrangements**





We
      do not
      have any off-balance sheet arrangements.





**Contractual
      Obligations**







Payments
                  due by periodObligations
              
              Total
              
              1
                  Year
              
              1-2
                  Years
              
              2-3
                  Years
              
              3-5
                  YearsLong-Term
                  Debt Obligations
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-Capital
                  Lease Obligations
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-Operating
                  Lease Obligations
              
              $
              1,059,031
              
              $
              660,741
              
              $
              291,464
              
              $
              106,826
              
              
              -0-Purchase
                  Obligations
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-Other
                  Long-Term Liabilities
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-Total
                  Contractual Obligations
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-
              
              
              -0-
  30





**ITEM
      3**  **Quantitative
      and Qualitative Disclosures About Market Risk**





Our
      primary operations are located in China. As a result we are exposed to gains
      and
      losses resulting from fluctuations in foreign currency exchange rates relating
      to certain sales and product purchases. We are also exposed to foreign currency
      gains and losses resulting from domestic transactions that are not denominated
      in U.S. dollars, and to fluctuations in interest rates related to our variable
      rate debt. Furthermore, we are exposed to gains and losses resulting from the
      effect that fluctuations in foreign currency exchange rates have on the reported
      results in our consolidated financial statements due to the translation of
      the
      operating results and financial position.





Our
      primary financial instruments are cash in banks and money market instruments.
      We
      do not believe that these instruments are subject to material potential
      near-term losses in future earnings from reasonably possible near-term changes
      in market rates or prices. We do not have derivative financial instruments
      for
      speculative or trading purposes. We are not currently exposed to any material
      currency exchange risk.





**ITEM
      4**  **Controls
      and Procedures**





We
      conducted an evaluation, with the participation of our Chief Executive Officer
      and Chief Financial Officer, of the effectiveness of the design and operation
      of
      our disclosure controls and procedures, as defined in Rules 13a-15(e) and
      15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange
      Act, as of July 31, 2007, to ensure that information required to be disclosed
      by
      us in the reports filed or submitted by us under the Exchange Act is recorded,
      processed, summarized and reported, within the time periods specified in the
      Securities Exchange Commission’s rules and forms, including to ensure that
      information required to be disclosed by us in the reports filed or submitted
      by
      us under the Exchange Act is accumulated and communicated to our management,
      including our principal executive and principal financial officers, or persons
      performing similar functions, as appropriate to allow timely decisions regarding
      required disclosure. Based on that evaluation, our Chief Executive Officer
      and
      Chief Financial Officer have concluded that as of July 31, 2007, our disclosure
      controls and procedures were
      effective to ensure the timely collection, evaluation and disclosure of
      information relating to the Company.





**Changes
      in Internal Control over Financial Reporting**





There
      were no changes in our internal control over financial reporting, as defined
      in
      Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently
      completed fiscal quarter that have materially affected, or are reasonably likely
      to materially affect, our internal control over financial
      reporting.




31




**PART
      II** **- OTHER INFORMATION**





**ITEM
      1**  **Legal
      Proceedings**





We
      are
      not a party to, or threatened by, any litigation or procedures.





**ITEM
      1A**  **Risk
      Factors**





There
      are
      no material changes to the risk factors in our most recent Transitional Report
      on Form 10-K/A for the fiscal year ended October 31, 2006.





**ITEM
      2**  **Unregistered
      Sales of Equity Securities and Use of Proceeds**





On
      May
      17, 2007, we issued warrant to acquire 15,000 shares of our common stock at
      $3.02 price per share to Mr. Magnus Moliteus, one of our Directors, as
      compensation for him agreeing to become a member of our Board of Directors.
      The
      issuance was exempt from registration pursuant to Section 4(2) of the Securities
      Act of 1933, and the shareholders were accredited.





**ITEM
      3**  **Defaults
      Upon Senior Securities**





There
      have been no events that are required to be reported under this
      Item.





**ITEM
      4**  **Submission
      of Matters to a Vote of Security Holders**





There
      have been no events that are required to be reported under this
      Item.





**ITEM
      5**  **Other
      Information**





*Departure
      of Directors or Principal Officers; Election of Directors; Appointment of
      Principal Officers*





On
      September 16, 2006, we entered into an oral agreement with Ms. Edith Kong under
      which she was hired to be our interim Chief Financial Officer and appointed
      to
      the Board of Directors. On January 25, 2007, Ms. Kong resigned from her
      positions as interim Chief Financial Officer and a Director. At the time of
      her
      resignation we agreed to pay Ms. Kong $32,000 in cash for her services. This
      is
      the only compensation we agreed to pay Ms. Kong for her services.





Effective
      on January 25, 2007, our Board of Directors hired Mr. Wang Zuoliang as our
      interim Chief Financial Officer to replace Ms. Kong. Mr. Wang has served as
      Chief Accounting Officer of Harbin Renhuang Pharmaceutical Co. Ltd., our
      wholly-owned subsidiary, since 2005. Mr. Wang has more than 10 years experience
      in accounting and is familiar with our financial condition and the internal
      preparation of our financial statements. From 2004 to 2005, Mr. Wang served
      as
      the Chief Financial Officer of Harbin Huijiabei Food Co. Ltd. From 2001 to
      2004,
      Mr. Wang served as the manager of the accounting department of China Resource
      Breweries Limited, Harbin Office. Mr. Wang Zuoliang graduated from Qiqihaer
      Mechanic Institute in 1994 with a bachelor degree in engineering
      management.





We
      are in
      the process of interviewing candidates for a permanent Chief Financial Officer
      and hope to have a new permanent Chief Financial Officer hired in the near
      future. Once a new Chief Financial Officer is hired we will file a Form 8-K
      with
      information regarding the Chief Financial Officer, as required.





Effective
      on January 25, 2007, Mr. Pi Dianjun resigned from his position as a
      Director.





32


Effective
      on January 25, 2007, our Board of Directors appointed Mr. Andy Wu to the Board
      of Directors as an independent Director and as Chairman of our Audit Committee.
      Mr. Wu is currently a Tax Manager at PWC Beijing responsible for the
      overall operations of the Dalian office, including IIT filing, tax health check,
      assistance on setting up new enterprise/RO, assistance in tax audit defense,
      tax
      due diligence, tax review for IPO projects, assistance in negotiation for deemed
      profit rates, and general tax and business consulting. Mr. Wu has held this
      position since January, 2006. During 2005, Mr. Wu was an Assistant Tax Manager
      at KPMG Shanghai, with his main responsibilities involving general tax and
      business consulting and due diligence work. From August 2004 to March 2005,
      Mr.
      Wu was a Senior Tax Consultant with Deloitte’s Suzhou Office, primarily
      responsible for tax review, Due Diligence, IIT compliance, and general tax
      advisory projects. From March 1998 to August 2001, Mr. Wu was the Chief Officer
      of the Collections Division for the Nangang Branch of Harbin State Tax Bureau,
      where he was responsible for managing the operations of the Collections
      Division. Mr. Wu received a Doctorate Finance and Taxation from Xiamen
      University in June 2004, a Master in Finance and Taxation from Dongbei
      University of Finance in January 2001, and his Bachelor in Taxation from Xiamen
      University in July 1992.





Effective
      on April 16, 2007, our Board of Directors appointed Mr. Magnus Moliteus to
      the
      Board of Directors as an independent Director. Since 2001, Mr. Moliteus has
      been a consultant to the healthcare industry and Chairman of COM Consulting,
      Inc., a privately held firm, which enhances Swedish-American relations
      particularly between health care companies. From 1995 to 2001, Mr. Moliteus
      served as Executive Director of Invest at Sweden Agency, U.S., a Swedish
      government agency. From 1977 to 1990, he was Chief Executive Officer of
      Pharmacia, Inc. (now owned by Pfizer, Inc.).





As
      compensation for his services as a Director, Mr. Moliteus will receive options
      to acquire 15,000 options at signing, plus an additional 10,000 options and
      $10,000 annually thereafter, with the first payment to be paid at the end of
      July, 2007. On May 17, 2007, Mr. Moliteus received his 15,000 options, at an
      exercise price of $3.02, in accordance with his agreement.





*Correction
      of Audit Fees in Annual Report on Form 10-K/A*





Our
      Annual Report on Form 10-K/A for the fiscal year ended October 31, 2006 filed
      with the Securities and Exchange Commission on February 22, 2007 reported the
      $125,000 in fees Schwartz Levitsky Feldman LLP billed us for the audit of our
      financial statements under “Audit-Related Fees.” These fees should have been
      listed under “Audit Fees” and not under “Audit-Related Fees.”





*Acquisition
      of Extracting Factory*





On
      March
      3, 2007, we acquired all the assets and assumed a bank loan with accrued
      interest of Qingyang Extracting Factory, from Zhongfa Industrial Group Yerui
      Pharmaceutical Co., Ltd. for a total amount of RMB 3.7 million or approximately
      USD $480,000. The assets acquired included inventories, customer purchase
      orders, accounts receivables, corporate name, patents, trademarks, equipment,
      customer lists and records and other assets that are used or held for use in
      connection with Business of Qingyang Extracting Factory. We paid USD $310,000
      in
      cash and assumed a bank loan with China Agriculture Bank in the principal amount
      of USD $140,000 and accrued interest of USD $30,000 collateralized by the
      acquired assets. The transaction closed on March 3, 2007, and we have paid
      the
      cash portion of the consideration USD $310,000 (RMB 2,415,000). The Qingyang
      Extracting Factor, located in Yanshou Township Harbin, China, is a manufacturing
      facility that processes raw herbal plants into extracts, which is the
      intermediate material for Chinese herbal medicine finished products. The factory
      is capable of processing approximately 18,000 tons of herbal raw materials
      into
      extract, doubling our current herbal extracting capacity.





33


**ITEM
      6**  **Exhibits**





(a)
            Exhibits





3.1
                (1)
            
            Restated
                Articles of Incorporation, as filed with the Nevada Secretary of
                State on
                April 21, 2003.3.2
                (5)
            
            Amendment
                to Articles of Incorporation, as filed with the Nevada Secretary
                of State
                on July 28, 2006.3.3
                (1)
            
            Second
                Restated Bylaws10.1
                (2)
            
            Common
                Stock Purchase Agreement dated September 19, 2005.10.2
                (2)
            
            Securities
                Purchase Agreement dated September 16, 2005.10.3
                (3)
            
            Reorganization,
                Stock and Asset Purchase Agreement dated September 30,
                2005.10.4
                (3)
            
            Stock
                Purchase Agreement dated September 30, 2005.10.5
                (4)
            
            Securities
                Purchase Agreement dated September 16, 2005.10.6
                (5)
            
            Loan
                Agreement with Heilongjiang Yuejintiande Building and Installation
                Project
                Co.,Ltd10.7
                (6)
            
            Acquisition
                Agreement between Harbin Renhuang Pharmaceutical Co., Ltd. and Zhongfa
                Industrial Group Yerui Pharmaceutical Co., Ltd., dated February 28,
                200721.1
                (5)
            
            Subsidiaries
                of the Registrant31.1
            
            Rule
                13a-14(a)/15d-14(a) Certification of Chief Executive
                Officer31.2
            
            Rule
                13a-14(a)/15d-14(a) Certification of Chief Financial
                Officer32.1
            
            Chief
                Executive Officer Certification Pursuant to 18 USC, Section 1350,
                as
                Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
                2002.32.2
            
            Chief
                Financial Officer Certification Pursuant to 18 USC, Section 1350,
                as
                Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
                2002.





(1)
            Incorporated
                by reference to our Current Report on Form 8-K dated April 21, 2003,
                filed
                with the Commission on April 22,
                2003.


(2)
            Incorporated
                by reference from our Current Report on Form 8-K filed with the Commission
                on September 23, 2005.


(3)
            Incorporated
                by reference from our Current Report on Form 8-K filed with the Commission
                on October 3, 2005.


(4)
            Incorporated
                by reference from our Current Report on Form 8-K filed with the Commission
                on October 14, 2005.


(5)
            Incorporated
                by reference from our First Amended Transition Report on Form 10-K/A
                filed
                with the Commission on February 22,
                2007.


(6)
            Incorporated
                by reference from our Quarterly Report on Form 10-Q for the period
                ended
                January 31, 2007, filed with the Commission on March 19,
                2007.




34




**SIGNATURES**





In
      accordance with the requirements of the Exchange Act, the registrant caused
      this
      report to be signed on its behalf by the undersigned, thereunto duly
      authorized.











**Renhuang
                Pharmaceuticals, Inc.**Dated:
                September 19, 2007
            
            /s/
                Li ShaomingBy:
            Li
                ShaomingPresident
                andChief
                Executive OfficerDated:
                September 19, 2007
            
            /s/
                Zouliang WangBy:
            Zuoliang
                WangInterim
                Chief Financial Officer





35